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Table 1a
Baseline Characteristics
Patient Characteristic Bu-Cy Cy-Bu P Value
Total patients 18 22
Sex .424
Male 15 16
Female 3 6
Age
Median (range) 17 (1-50) 16 (1-48) .85
Mean 21.83 22.81 .899
<14 yr 7 7
14-45 yr 10 13
>45 yr 1 2
Underlying disease .415
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S270Background: Sickle cell disease (SCD) affects 72,000 in-
dividuals in the United States and causes considerable
morbidity and mortality. Hematopoietic stem cell trans-
plantation (HSCT) is the only cure for patients with SCD.
Multiple studies show matched sibling transplants after
myeloablative (MAB) conditioning have acceptable results,
but with potential long-term complications, like endocrine
and fertility issues. Only 14% of SCD patients will have
acceptable sibling donors, and results have been less
promising with higher rates of transplant related mortality
(TRM) using alternative donors after MAB conditioning.
Historically, only pediatric patients were considered can-
didates for HSCT, but a recent study demonstrated that
young adult SCD patients may be able to tolerate a RIC
HSCT with minimal complications. In an attempt to
minimize the risk of TRM while still maximizing the
available donors, this study examines the use of a RIC
regimen for either matched sibling or alternative donor
HSCT in SCD patients ages 2-30.
Methods: Patients were deemed eligible for matched sibling
HSCT if they had SCD, and for alternative donor HSCT if they
had SCDwith severe features with a 9-10/10 unrelated donor
or 5-6/6 UCB in the donor registry. The conditioning regimen
consisted of Alemtuzumab, Fludarabine, and Melphalan.
Post-HCST, donor chimerism and hemoglobin S (HbS) per-
centages were followed closely, and there was strict moni-
toring for post-HSCT complications, including graft rejection,
graft vs. host disease (GVHD), infectious complications, and
other post-HSCT issues.
Results: 11 patients (8 related donors, 3 unrelated donors)
with median age of 8.1 years (range: 2.3-23 years) were
enrolled. For related HSCT, the probabilities of primary
neutrophil & platelet engraftment, grade II-IV acute GVHD,
chronic GVHD, and graft rejectionwere 100%, 27%, 12.5%, and
0%, respectively. Donor chimerisms ranged from 96-100%
with HbS% between 0-43%, with median follow-up of 19
months (range: 3-24months). Probability of 1-yr DFS and OS
were 100% & 100%. For alternative donor HSCT, the proba-
bilities of primary neutrophil & platelet engraftment, grade
II-IV GVHD, chronic GVHD, and graft rejection were 100%,
33%, 33%, and 33%, respectively. Donor chimerisms ranged
from 0-100%with HbS% between 0-18%, with median follow-
up of 8 months (range: 2-25 months). Probability of 1-yr DFS
and OS were 33% & 66%.
Conclusions: Our results show that this RIC regimen fol-
lowed by matched sibling HSCT is well tolerated, but the
results were discouraging for alternative donor HSCT.
Because of this, we are currently developing a protocol using
post-transplant cyclophosphamide in alternative donor
HSCT for SCD.AML 14 12
ALL 3 4
CML 1 3
MDS 0 2
Primary myeloﬁbrosis 0 1
Stage of disease .984
Early 3 4
Intermediate 8 10
Late 7 8
Pre-transplant remission status .482
CR 11 11
Not in CR 7 11
Performance status (ECOG) .314
0 4 3
1 9 16
HSCT comorbidity index .341
0 14 15
1 1 5
2 2 2
3 1 0384
Pre-Transplant Consolidation Chemotherapy for Acute
Lymphocytic Leukemia (ALL) Does Not Impact Outcomes
after Allogeneic Hematopoietic Cell Transplantation
(alloHCT)
Nelli Bejanyan 1, Aleksandr Lazaryan 2, Ryan Shanley 2,
Sagar Patel 3, Claudio Brunstein 2, Veronika Bachanova 2.
1 University of Minnesota Medical Center, Minneapolis, MN;
2University of Minnesota Medical Center, Minneapolis, MN;
3University of Minnesota Medical School, Minneapolis, MN
Most adult ALL protocols include consolidation chemotherapy,
yet whether the consolidation is beneﬁcial in patients under-
going alloHCT in ﬁrst complete remission (CR1) remains un-
certain. We therefore studied the impact of consolidation
chemotherapy on transplant outcomes of 75 consecutive ALLpatientswho received alloHCT in CR1 between 2004 and 2013.
Patientswho received at least 1 cycle of consolidation (n¼51; 1
cycle, n¼25;2 cycles, n¼26)were compared to thosewithout
consolidation (n¼24) chemotherapy prior to alloHCT. The
median age of entire cohort was 42 years (range, 19-67) and
59% were males. Half had Ph+ ALL and 16% had CNS leukemia.
Patients received median of 2 cycles of induction chemo-
therapy (range, 1-5), and the median time from diagnosis to
CR1 was 1.6 months (range, 1.1-2.9). Among 54 patients
evaluable for minimal residual disease (MRD), 42 were MRD
negative prior to alloHCT. Most patients received myeloa-
blative conditioning (67%) and umbilical cord blood (UCB, 63%)
alloHCT. Patients in 1 consolidation group were more often
transplanted after 2008 (75% vs. 31%, p<0.01) as compared to
no consolidation group, however other patient, disease and
transplant characteristics were similar in both groups. At a
median follow up of 4 years (range,1-8), patients treated with
1 cycles of consolidation versus no consolidation had similar
1-year non-relapse mortality (24% vs. 29%, p¼0.23), 2-year
leukemia relapse (23% vs. 25%, p¼0.44), leukemia-free survival
(48%vs. 36%,p¼0.18) andoverall survival (61%vs. 45%,p¼0.15),
respectively. Cumulative incidence of relapse was lower in
MRD negative patients (17% vs 50% MRD+, p¼0.03) and UCB
recipients (15%vs 37% related donor, p¼0.02). Our data suggest
that ALL patients with available donor undergoing alloHCT in
CR1may not beneﬁt from further pre-transplant consolidation
chemotherapy.385
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Table 2
Results
Outcome Bu-Cy Cy-Bu P
ANC recovery .119
Median (range) 14 (11-30) 11 (8-32)
Mean  SD 15.64  4.63 14.18  5.63 .391
Platelet recovery
Median (range) 21 (17-44) 16 (11-27) .008
Mean  SD 25.30  8.75 18  5.17 .005
RBCs transfused
Median (range) 3 (0-8) 2 (0-13) .48
Mean  SD 3.52  2.62 3.40  3.76 .911
Platelets transfused
Median (range) 6 (1-10) 4 (1-15) .166
Mean  SD 6.17  2.98 4.95  3.61 .267
Days of GCSF
Median (range) 18 (12-36) 14 (9-37) .126
Mean  SD 18.66  5.48 16.90  6.66 .375
D100 complete donor
chimerism
Achieved 9 (90%) 12(85.71%) 1.000
Not achieved 1 2
Days of hospital admission
Median (range) 18 (12-36) 14 (9-37) .48
Mean  SD 26.11  9.84 24.31  9.25 .557
Transplant response
CR (% age) 15/17 (88.24) 19/22 (86.36) 1.000
No of antibiotics
Mean  SD 4.38  2.14 3.68  2.25 .319
<5 8 13 .356
5 10 9
Days of AMA
Median 13 (0-34) 13 (0-36) .83
<14 8 11 .726
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Introduction: Conditioning regimens are an important
issue determining the outcome of hematopoietic stem cell
transplantation (HSCT). Altering the administration order
of Busulphan (Bu) and Cyclophosphamide (Cy) during
conditioning from conventional method of administering
Bu followed by Cy had resulted in an improved
toxicity proﬁle in few animal and subsequent human
studies. However the data substantiating this approach is
limited.
Methods: We retrospectively analyzed all consecutive pa-
tients receiving allogeneic stem cell transplant (Allo SCT)
with myeloablative conditioning from 2009 to 2013. A
total of 40 patient received Allo SCT of which 18 patient
received Bu-Cy and 22 patients received Cy-Bu condi-
tioning regimen. The BueCy conditioning regimen con-
sisted of i.v. Bu 0.8mg/kg administered every 6h (16
doses) on days 7 to 4, followed by i.v. Cy 60mg/kg on
days 3 and 2. Patients with the CyeBu regimen
received i.v. Cy 60mg/kg on days 7 and 6; followed by
i.v. Bu 0.8mg/kg administered every 6hr (16 doses) on
days 5 to 2. GVHD prophylaxis was given with Cyclo-
sporine A and methotrexate. Common Terminology
Criteria for Adverse Events version 3.0 (CTCAE) was used
for assessment of toxicity. The diagnosis of sinusoidal
obstruction syndrome (SOS) was based on modiﬁed Seat-
tle criteria.Table 1b
Baseline Characteristics
Transplant Characteristics Bu-Cy Cy-Bu P Value
Time from diagnosis
to transplant
Median in days (range) 253 (66-2161) 476 (38-3470)
1 yr 9 6 .140
>1 yr 9 16
Mean (d)  SD 548.1 675 .567
Transplant period
2009-2011 16 6 <.001
2012-2013 2 16
HLA matching
HLA identical (6/6) 17 21 .884
HLA mismatch (5/6) 1 1
Donor
Matched sibling 17 16 .884
UCB 1 1
Donor age
Median (range) 20 (0-47) 16 (0-50)
<18 yr 7 11 .781
18-30 yr 4 4
>30 yr 7 7
Donor sex
Male 5 14 .034
Female 12 8
Sex mismatch 12 13 .458
Female donor in
male patient
11 7 .064
Harvest source
Peripheral blood (PB) 15 21 .269
Bone marrow (BM) 2 0
Cord blood (UCB) 1 1
CD34 count (106 cells/kg)
Median (range) 4.8 (1.8-12) 5.7 (2-11) .40
Mean  SD 5.12  2.60 5.66  2.37 .499
5 10 7 .131
5 8 15
CD3 count (107 cells/kg)
Median (range) 16 (7-62.7) 12 (1-40)
Mean 25.5 17.5 .200
>14 10 11
Use of Gram positive AMA
No 2 8 .067
Yes 16 14
Hepatotoxicity
Grade 2-4 10/18 (55.56%) 6/22 (27.27%) .069
Grade 3-4 10/18 (55.56%) 3/22 (13.64%) .030
Nephrotoxicity
Grade 2-4 8/18 (44.44%) 2/22 (09.09%) .010
Grade 3-4 3/18 (16.67%) 1/22 (4.55%) .204
Mucositis
Grade 3-4 6/18 (33.33%) 6/22 (27.27%) .677
Grade 2-4 12/18 (66.66%) 15/22 (68.18%) .919
Any grade 3-4 toxicity 10/18 (55.56%) 9/22 (40.91%) .356
No of organs with grade
3-4 toxicity
Mean 0.5  0.20 0.94  1.05 .114
Single 13 20 .122
Multiple 5 2
D30 TRM
Yes 3 (16.67%) 0 .083
No 15 22
D100 TRM
Yes 4 (22.22%) 2 (10%) .395
No 14 20
Follow up
Median 28.67 mo 7.6 moResults: Pre-transplant characteristics were comparable in
the two cohorts (Table 1a and 1b). Time to platelet
engraftment was earlier in the Cy-Bu cohort (21 days vs.
16 days; P¼0.008) (Table 2).Treatment related side effects
were similar in both the groups except hepatotoxicity
(grade3-4) and nephrotoxicity (grade2-4)which was higher
in Bu-Cy as compared to Cy-Bu group (10 (55.16%) vs. 3
(13.64%); p¼0.03) and (8 (44.44%) vs 2 (9.09%);p¼0.010)
respectively. There was no signiﬁcant difference in treat-
ment related mortality (TRM) at day 100; however there
was trend towards higher TRM at day 30 in Bu-Cy group
Table 3
Acute GVHD Characteristics
Variables Categories Bu-Cy Cy-Bu P
Acute GVHD Cumulative
incidence
3/18 (16.67%) 5/22(22.73%) .709
Median day
of onset
18 d (15-95) 28 d (16-55)
Mean  SD 39.75  37.48 33.12  15.90 .667
Grade of
acute GVHD
Grade 1 0 3 .236
Grade 2-4 4 4
Skin Stage 1 3 4 1.000
Stage 2-4 1 2
Liver Stage 1 1 0 .400
Stage 2-4 1 3
Gut Stage 1 0 0 1.000
Stage 2-4 2 2
Mortality Cumulative
incidence
1 (25%) 2 (28.57%) 1.000
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S272(3 vs. none; p¼0.083).There was no difference in aGVHD
incidence, grade or stage of organ involved between the 2
groups.
Conclusion: As in previous studies hepatotoxicity in the
present analysis was found to be less in patients who
received Cy-Bu as the conditioning regimen and there was
earlier platelet engraftment in this group. These ﬁndings
suggest Cy-Bu has better toxicity proﬁle than conventional
Bu-Cy regimen. However further prospective studies are
required to conﬁrm these ﬁndings.Figure 1386
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The Anthony Nolan volunteer hematopoietic stem cell (HSC)
donor registry recently encountered two episodes of hema-
turia following the use of granulocyte colony stimulating
factor (G-CSF), highlighting how serious underlying medical
conditions may go unnoticed despite rigorous assessment.
A 28-year-old Caucasian male donor had an unremarkable
medical history at work-up. He reported an episode of self-
limiting frank hematuria one year previously. At that time, he
was diagnosed with an episode of possible haemorrhagic
cystitis. At the pre-donation assessment his creatinine was.
